Dr. Marc Matrana - Cancer Advocacy ...

Dr. Marc Matrana, MD

Claim this profile

Ochsner Medical Center Jefferson

Expert in Lung Cancer
Studies Cancer
26 reported clinical trials
65 drugs studied

About Marc Matrana, MD

Education:

  • Earned an MD from Louisiana State University School of Medicine, New Orleans, in 2007.
  • Completed Residency in Internal Medicine at Ochsner Clinic Foundation in 2010.
  • Completed Fellowship in Hematology/Oncology at Ochsner Clinic Foundation in 2013.

Experience:

  • Assistant Professor of Medicine at the University of Queensland School of Medicine – Ochsner Clinical School.
  • Director of the Alvin J. Blumkin Center for Innovation and Research in Lung Cancer at Ochsner Health.
  • Specializes in lung cancer and thoracic oncology.

Area of expertise

1Lung Cancer
Global Leader
Marc Matrana, MD has run 13 trials for Lung Cancer. Some of their research focus areas include:
Stage III
Stage II
Stage IV
2Cancer
Marc Matrana, MD has run 8 trials for Cancer. Some of their research focus areas include:
Stage IV
RET positive
Stage III

Affiliated Hospitals

Image of trial facility.
Ochsner Medical Center Jefferson
Image of trial facility.
Ochsner High Grove

Clinical Trials Marc Matrana, MD is currently running

Image of trial facility.

Nivolumab + Ipilimumab + Sargramostim

for Advanced Melanoma

This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable) and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Colony-stimulating factors, such as sargramostim, may increase the production of white blood cells. It is not yet known whether nivolumab and ipilimumab are more effective with or without sargramostim in treating patients with melanoma.
Recruiting1 award Phase 2 & 323 criteria
Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria

More about Marc Matrana, MD

Clinical Trial Related5 years of experience running clinical trials · Led 26 trials as a Principal Investigator · 7 Active Clinical Trials
Treatments Marc Matrana, MD has experience with
  • Pembrolizumab
  • Nivolumab
  • Ipilimumab
  • Gemcitabine
  • Gemcitabine Hydrochloride
  • Docetaxel

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Marc Matrana, MD specialize in?
Is Marc Matrana, MD currently recruiting for clinical trials?
Are there any treatments that Marc Matrana, MD has studied deeply?
What is the best way to schedule an appointment with Marc Matrana, MD?
What is the office address of Marc Matrana, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security